Systemic tumor regression in patients with indolent B cell lymphoma before vaccine (on left) and after vaccine. Photo: Joshua Brody/Mount Sinai Health System

Scientists announced a preliminary success in devising a cancer "vaccine" that was able to help prime the immune system to attack lymphoma cancer tumors in some patients, leading to a period of remission, according to a clinical study of 11 patients published in Nature Medicine Monday.

Why it matters: Indolent non-Hodgkin’s lymphomas (iNHLs) tend to be a slow-growing cancer that is incurable with standard therapy and poorly responsive to a newer type of treatment called checkpoint blockade. Scientists have been seeking ways to broaden the response of immunotherapy to more patients, and a therapeutic cancer vaccine is one option that's under consideration.

Background: There are many types of immune cells in the body, with dendritic and T-cells both playing powerful but distinct roles. Dendritic cells detect an infection or cancer cells and alert the T-cells to attack en masse.

  • But, cancer cells often elude discovery by the immune system for a variety of reasons.

This new type of treatment is designed to force the tumor to expose itself and trigger the immune response.

What they did: The trial, which began in 2013, tested a three-pronged attack as part of the treatment. The tests were done first in animals and then in 11 human patients, most of whom had iNHLs, says study author Joshua Brody, director of the lymphoma immunotherapy program at the Icahn School of Medicine at Mount Sinai Hospital.

  • The treatment was injected into one of the tumor sites to spur the tumor to make a therapeutic "vaccine" that triggers the immune system.

How it works: Each of the 3 components in the treatment plays an important role, Brody says. Separately, each have shown modest improvements in patient outcomes, but together they show a stronger impact.

  • The components recruit dendritic cells to the tumor, and help the immune system identify the threat by activating the body's detection system. The ultimate goal is to have T-cells proliferating and spreading throughout the body to kill any cancer cells.

What they found: The mouse trial was robust and successful, while the trial in the human participants showed a strong response in some, but not all, patients.

  • The "vaccine was dramatically successful in some patients, with partial and complete remissions (of non-injected tumors) lasting for months to years," Brody says.
  • For non-responders, they found the patients still had developed new T-cells and their tumors had become responsive to a type of treatment called PD1 blockade, prompting a followup trial of the combined therapy.

What they're saying: Several experts who were not part of this study tell Axios it shows some promising results, but also caution that the study was small and only helped some of the patients.

  • James Rubenstein, professor in residence at UCSF's Department of Medicine, says this offers a roadmap for future research that emphasizes the potential strategic role of dendritic cells in new treatments. "This particular study is promising because of the incorporation of multiple strategies including the successful local recruitment of dendritic cells," he says.
  • Pavan Reddy, deputy director of the University of Michigan's Comprehensive Care Center, calls it an "exciting" study. But, he adds, "the human studies, while exciting, must be emphasized as preliminary. ... [I]t worked only in a few patients. Furthermore, indolent lymphomas typically progress slowly, so the quality and duration of the responses even from the limited responders will need to be assessed."

What's next: Based on the early success, the research team has already started a new clinical trial for patients with lymphoma, breast cancer and head/neck cancer that adds the fourth component — the PD1 blockade — in the hope of getting that last resistant set of patients to respond.

Go deeper

Updated 20 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 11:30 p.m. ET: 31,478,387 — Total deaths: 968,726 Total recoveries: 21,622,862Map.
  2. U.S.: Total confirmed cases as of 11:30 p.m. ET: 6,895,685 — Total deaths: 200,768 — Total recoveries: 2,646,959 — Total tests: 96,612,436Map.
  3. Health: The U.S. reaches 200,000 coronavirus deaths — The CDC's crumbling reputation — America turns against coronavirus vaccine.
  4. Politics: Elected officials are failing us on much-needed stimulus.
  5. Business: Two-thirds of business leaders think pandemic will lead to permanent changes — Fed chair warns economy will feel the weight of expired stimulus.
  6. Sports: NFL fines maskless coaches.

Trump pushes to expand ban against anti-racism training to federal contractors

Trump speaking at Moon Township, Penns., on Sept. 22. Photo: Mandel Ngan/AFP via Getty Images

President Trump announced late Tuesday that the White House attempt to halt federal agencies' anti-racism training would be expanded to block federal contractors from "promoting radical ideologies that divide Americans by race or sex."

Why it matters: The executive order appears to give the government the ability to cancel contracts if anti-racist or diversity trainings focused on sexual identity or gender are organized. The memo applies to executive departments and agencies, the U.S. military, federal contractors and federal grant recipients.

Dan Primack, author of Pro Rata
4 hours ago - Economy & Business

GoodRx prices IPO at $33 per share, valued at $12.7 billion

Illustration: Sarah Grillo/Axios

GoodRx, a price comparison app for prescription drugs at local pharmacies, on Tuesday night raised $1.14 billion in its IPO, Axios has learned.

By the numbers: GoodRx priced its shares at $33 a piece, above its $24-$28 per share offering range, which will give it an initial market cap of around $12.7 billion.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!